The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...
BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press ...
WASHINGTON--(BUSINESS WIRE)--Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food and Drug Administration Drug Development Tool ...
The landscape of modern healthcare is undergoing a seismic shift, moving away from "one-size-fits-all" treatments toward a ...
We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...
According to Mordor Intelligence, the proteomics market size was valued at USD 29.92 billion in 2025 and projected to grow from USD 33.47 billion in 2026 to reach USD 58.66 billion by 2031, at a CAGR ...
Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development BOSTON--(BUSINESS WIRE)-- Genialis, the RNA biomarker company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results